November 18, 2025

Roswell Park at ASH 2025

Roswell Park invites you to come meet some of our nationally recognized experts in transplant and cellular therapy and hematologic malignancies at this year’s ASH conference in Orlando, taking place December 6-9, 2025. 

Roswell Park Comprehensive Cancer Center

November 05, 2025

Roswell Park Experts Share Latest Hematology Research at 67th ASH Annual Meeting

Experts from Roswell Park Comprehensive Cancer Center will discuss their latest discoveries at the 67th annual meeting of the American Society of Hematology (ASH) December 6-9 in Orlando, Florida.

Roswell Park Comprehensive Cancer Center

October 31, 2025

A Young Hematologist’s Take on ICML 2025

From Dr. Bruce Cheson’s electric speech on how it all started with pentostatin in hairy cell leukemia, to the introduction of bendamustine in indolent lymphoma, to the development of R-squared (an inn...

The ASCO Post

October 19, 2025

ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors

Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy.

Dana-Farber

October 13, 2025

Join Roswell Park Revolutionaries for Cell Therapy Symposium at ASH

Renier Brentjens, MD, PhD, and Marco Davila, MD, PhD, will host a satellite symposium during this year’s ASH meeting to discuss the evolving landscape of CAR T-cell therapy.

Roswell Park Comprehensive Cancer Center

October 10, 2025

Patients Value Communication Skills From Cancer Surgeons Across Six Key Areas

“Surgical oncologists play a pivotal role in the care of patients with many types of cancer, often serving as the initial point of contact for health-care delivery. With this research, we sought to pr...

The ASCO Post

October 08, 2025

Use of Obecabtagene Autoleucel CAR T-Cell Therapy for B-Cell Acute Lymphocytic Leukemia

Treatment with obecabtagene autoleucel was the focus of the phase Ib/II multicenter FELIX study of more than 100 adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).1 The init...

The ASCO Post

September 03, 2025

Miami Brain Symposium, Eighth Annual

The Miami Brain Symposium will focus on state-of-the-art approaches to the management of primary and metastatic central nervous system tumors, along with current standards of care and a look at future directions. This symposium will engage participants as the expert faculty navigate through complex cases, novel treatment strategies and panel discussions.

Baptist Health South Florida

September 02, 2025

AACR 2025: Pretrained AI Models Could Help Accurately Diagnose Nonmelanoma Skin Cancers in Resource-Limited Settings

Researchers explored whether artificial intelligence (AI) models pretrained on vast data sets may outperform standard baseline models in identifying nonmelanoma skin cancers, according to findings pre...

The ASCO Post